Table 2:
Consensus opinion recommendations for protocol monitoring of islet allografts.
| Static Metabolic Testing | ||||||
|---|---|---|---|---|---|---|
| Not monitored routinely |
≤ 1 month | Every 1-3 months |
Every 6 months |
Annually | Consensus Opinion | |
| Weight | 1 (5.6%) | 5 (27.8%) | 15 (83.3%) | 1 (5.6%) | 7 (38.9%) | Strongly recommended every 1-3 months |
| Fasting glucose | 0 (0.0%) | 7 (38.9%) | 14 (77.8%) | 3 (16.7%) | 7 (38.9%) | Strongly recommended every 1-3 months |
| HbA1c | 0 (0.0%) | 4 (22.2%) | 18 (100%) | 2 (11.1%) | 7 (38.9%) | Strongly recommended every 1-3 months |
| Fasting C-peptide | 1 (5.6%) | 5 (27.8%) | 15 (83.3%) | 3 (16.7%) | 8 (44.4%) | Strongly recommended every 1-3 months |
| Random C-peptide | 11 (61.1%) | 2 (11.1%) | 5 (27.8%) | 1 (5.6%) | 4 (22.2%) | Not recommended routinely |
| Fasting insulin | 11 (61.1%) | 1 (5.6%) | 4 (22.2%) | 2 (11.1%) | 5 (27.8%) | Not recommended routinely |
| Dynamic Metabolic Testing | ||||||
| OGTT | 16 (88.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (11.1%) | Not recommended routinely |
| MMTT, AST, IVGTT | 2 (11.1%) | 3 (16.7%) | 9 (50.0%) | 3 (16.7%) | 13 (72.2%) |
Suggested every 1-3 months
Recommended annually |
| Clamp | 17 (94.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (5.6%) | Not recommended routinely |
| CGM | 4 (22.2%) | 2 (11.1%) | 6 (33.3%) | 0 (0.0%) | 6 (33.3%) | Suggested based on institution availability |
| Immunologic Testing | ||||||
| DSA's | 2 (11.1%) | 2 (11.1%) | 6 (33.3%) | 4 (22.2%) | 10 (55.6%) | Suggested annually |
| Autoantibodies | 1 (5.6%) | 2 (11.1%) | 8 (44.4%) | 1 (5.6%) | 10 (55.6%) | Suggested annually |